PGCM
CDLX icon

Prescott Group Capital Management’s Cardlytics CDLX Stock Holding History

Prescott Group Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,500
Closed -$876K – 224
2018
Q3 		$876K Buy
3,500
+500
+17% +$108K 0.17% 130
2018
Q2 		$653K Buy
+3,000
New +$555K 0.12% 156

Other funds holding CDLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
CPV
Canaan Partners VIII Westport, Connecticut $31M AUM 45.38% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prescott Group Capital Management's CDLX Position: Q4 2018 in Review

Prescott Group Capital Management sold out of Cardlytics (CDLX) in Q4 2018, closing a stake of 3,500 shares — an estimated $876K sold.

Prescott Group Capital Management first reported a position in CDLX in Q2 2018 and held it in 2 quarters. The position peaked at $876K in Q3 2018. 61 funds tracked by Wall St. Rank hold CDLX as of Q4 2018.

  • Prescott Group Capital Management reported no remaining Cardlytics position as of Q4 2018 after selling out during the quarter.
  • Prescott Group Capital Management sold 3,500 Cardlytics shares in Q4 2018, an estimated $876K.
  • Prescott Group Capital Management first reported a position in Cardlytics in Q2 2018 and held it in 2 quarters.
  • Prescott Group Capital Management's Cardlytics position peaked at $876K in Q3 2018.
  • 61 funds tracked by Wall St. Rank held Cardlytics as of Q4 2018.

Based on Prescott Group Capital Management's 13F filing for Q4 2018, filed 11 Feb 2019.